Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 4/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12446975 | 0.92 | FDPS (0.46) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL5596441 | 0.83 | — | — | |
| SCHEMBL27390741 | 0.79 | ODC1 (0.50) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL8633558 | 0.77 | ODC1 (0.48) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL8634313 | 0.77 | ODC1 (0.48) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL29116696 | 0.74 | ODC1 (0.56) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL636456 | 0.74 | AKR1B1 (0.40) | FDPSPDE3AKMT2ATSHRHDAC11 | |
| SCHEMBL6632838 | 0.74 | ODC1 (0.56) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL515176 | 0.74 | LMNA (0.50) | LMNABLMPMP22PDE3ATHRB | |
| SCHEMBL2227906 | 0.72 | ACLY (0.54) | ODC1LMNABLMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | claimed |
| CN-1303991-C | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | WARNER LAMBERT CO (US) | 2007-03-14 | — | — | CN | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230103372-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4003323-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | Saol International Research Ltd. (BM) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021021277-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | SAOL INTERNATIONAL LIMITED (BM) | 2021-02-04 | — | — | WO | disclosed |
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | SAOL INTERNATIONAL LIMITED (BM) | 2020-10-06 | — | — | US | disclosed |
| US-10751312-B1 | — | — | 2020-08-25 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| CN-1303991-C | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | WARNER LAMBERT CO (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | ABAT, GABRA6, BCAT2 | ODC1 2843/4885LMNA 1629/4885BLM 3806/4885 |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | ODC1 2523/4885LMNA 2322/4885BLM 3293/4885 |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | ODC1 1116/4885LMNA 2881/4885BLM 1136/4885 |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | ODC1 1116/4885LMNA 2881/4885BLM 1136/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | ODC1 2523/4885LMNA 2322/4885BLM 3293/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | ODC1 1158/4885LMNA 2912/4885BLM 1040/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | ODC1 2523/4885LMNA 2322/4885BLM 3293/4885 |
| US-20230103372-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | ODC1 1158/4885LMNA 2912/4885BLM 1040/4885 |
| US-10751312-B1 | — | LIPA, CEL, GANC | ODC1 2341/4885LMNA 526/4885BLM 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.